Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR174 | Q9BXC1 | 1/20 | 1.00 |
| ▸ | PPARA | Q07869 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.54 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048962 | 0.84 | GPR174 (0.72) | GPR174RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL1305413 | 0.84 | KMT2A (0.75) | GPR174PPARANPC1KMT2AMAPT | |
| SCHEMBL8601340 | 0.84 | GPR174 (0.72) | GPR174RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL4104467 | 0.81 | MAPT (0.76) | GPR174PPARANPC1RAB9AKMT2A | |
| SCHEMBL4104949 | 0.78 | PPARA (0.68) | GPR174PPARANPC1RAB9AMAPT | |
| SCHEMBL1486040 | 0.78 | GPR174 (0.62) | GPR174NPC1RAB9AKMT2AMAPT | |
| SCHEMBL11888597 | 0.77 | NPC1 (0.76) | GPR174NPC1RAB9AKMT2AMAPT | |
| SCHEMBL21295527 | 0.76 | MEN1 (0.77) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL12810424 | 0.76 | MAPT (0.61) | GPR174RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL1065069 | 0.76 | GPR174 (0.61) | GPR174PPARANPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321083-A1 | Inhibitors of GPR174 and Uses Thereof | OMEROS CORP (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230321083-A1 | Inhibitors of GPR174 and Uses Thereof | OMEROS CORP (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | OMEROS CORPORATOIN | 2020-11-05 | — | — | US | disclosed |
| US-20200276190-A1 | Inhibitors of GPR174 and Uses Thereof | OMEROS CORP (US) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276190-A1 | Inhibitors of GPR174 and Uses Thereof | GPR174, GPR4, GPR88 | GPR174 1/4885PPARA 417/4885NPC1 1284/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | GPR174 2962/4885PPARA 2127/4885NPC1 1708/4885 |
| US-20230321083-A1 | Inhibitors of GPR174 and Uses Thereof | GPR174, GPR4, GPR88 | GPR174 1/4885PPARA 417/4885NPC1 1284/4885 |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | LPAR5, LPAR3, LPAR1 | GPR174 37/4885PPARA 642/4885NPC1 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.